Table 1a.
Nucleoside Reverse Transcriptase Inhibitor (NRTI) Associated Mutations
| Months of Failure* | ||||||
|---|---|---|---|---|---|---|
| Subject | 1-6 months | 7-12 months | 13-18 months | 19-24 months | 25-30 months | NRTI^ |
| 1 | - | - | D67N, A62V, M184V | D67N, M184V | D67N, A62V, T215Y, M184V | D4T/3TC |
| 2 | - | - | V75I, M184V | V75I, M184V | - | D4T/3TC |
| 3† | - | - | - | - | M184V | D4T/3TC |
| 4† | M184V | - | - | M184V | K65R, delT69##, M184V | D4T/3TC |
| 5 | M184V | M184V | M184V | T215Y, M184V | M41L, T215Y, M184V | D4T/3TC |
| 6 | M184V | K70R/K, M184V | K70R, K219E, M184V | - | D4T/3TC | |
| 7 | M184V | - | T215Y, M184V | - | T215F, M184V | ZDV/3TC |
| 8 | - | - | T215F, M184V | T215F, M184V | T215F, M184V | ZDV/3TC |
| 9 | M184V | - | - | M184V | - | ZDV/3TC |
| 10 | K65R | M184V | M184V | - | - | ZDV/3TC |
| 11 | M184V | M184V | M184V | - | - | ZDV/3TC |
| 12 | - | M184V | M184V | D67N/D, K70R/K, K219E/K, M184V | - | ZDV/3TC° |
| 13 | M184V | Y115F, M184V | M184V | - | - | ZDV/3TC/ABC# |
| 14 | M184V | M184V | M184V | - | - | ZDV/3TC/ABC# |
|
| ||||||
| M184V | 8/9 (89%) | 7/7 (100%) | 11/11 (100%) | 7/7 (100%) | 6/6 (100%) | |
| ≥1 TAM~ | 0/9 (0%) | 1/7 (0%) | 4/11 (36%) | 4/7 (57%) | 4/6 (67%) | |
| ≥2 TAM~ | 0/9 (0%) | 0/7 (0%) | 1/11 (9%) | 1/7 (0%) | 2/6 (33%) | |
*
estimated to start 90 days after ARV initiation;
^
patients also received nevirapine unless otherwise noted;
“-”
sample not available;
~
Thymidine analog mutations (TAMs) are underlined 14;
†
perinatal maternal use of single dose nevirapine was reported;
°
patient received efavirenz in lieu of nevirapine;
#
patients initially received ZDV/3TC/ABC due to concurrent anti-tuberculosis therapy and then changed to ZDV/3TC/NVP at 7 months.